Lyndra released clinical data in November 2018 demonstrating that its once-weekly dosage form can safely reside in the stomach with predictable pharmacokinetics. This was the first clinical study showing that it’s possible to convert a once-daily therapy into a weekly dosage. It demonstrated controlled, steady release of medication over an extended period, something no oral therapy had previously achieved. The pharmacokinetics data also showed that an ultra-long-acting oral dosage form has the potential to reduce drug side effects and improve efficacy. Lyndra has continued to expand its Phase I pipeline, with Lyndra stellates administered to 107 study participants (99 healthy volunteers and 8 patients) across five Phase I clinical studies to date. Included in their pipeline of targeted diseases are psychiatrics disorders, alzheimer's disease, HIV, transplant rejection, opioid use disorder, malaria vector control and oral contraceptives.